Recent pharmaceutical innovations have introduced a new avenue for weight loss: drugs based on gut hormones such as GLP-1 and ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Mounjaro, like Ozempic, is a GLP-1 inhibitor – a class of drugs developed to help people with diabetes regulate their blood glucose and insulin levels. However, Americans have increasingly been ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

Explore the world of weight loss drugs. Find out how GLP-1-based drugs can lead to significant weight loss, but also bone and ...

In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands Mounjaro and Zepbound, in India by 2025. The proposed dosages ranged from 2.5 ...

Weight loss drugs like Ozempic and Wegovy have seemingly taken over this year, curbing users appetites by making them feel ...

People struggling with their body weight experienced joy when new, more effective prescription drug options became the rage ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...

One lawmaker said the CT Department of Social Services told him the agency wasn’t paying for FDA-approved drugs because of ...